These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20356491)

  • 1. [Efficacy study of single-agent gemcitabine versus gemcitabine plus carboplatin in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer].
    Lou GY; Li T; Gu CP; Hong D; Zhang YP
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):100-2. PubMed ID: 20356491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
    Shi X; Yu XM; Zhang YP; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
    Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
    Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
    Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
    Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
    Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
    J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
    J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
    Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
    Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
    Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
    J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
    Treat JA; Gonin R; Socinski MA; Edelman MJ; Catalano RB; Marinucci DM; Ansari R; Gillenwater HH; Rowland KM; Comis RL; Obasaju CK; Belani CP;
    Ann Oncol; 2010 Mar; 21(3):540-547. PubMed ID: 19833819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
    Hasegawa Y; Miura D; Kitamura C; Suzuki T; Kobayashi K; Sato N
    Chemotherapy; 2013; 59(5):346-53. PubMed ID: 24821009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
    Sovak MA; Lutzker S; Zheng L; Guensch L; Joyce M; Schwartz S; Wu Y; Aisner J
    Lung Cancer; 2006 Aug; 53(2):177-81. PubMed ID: 16790293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
    Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
    Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
    Ansari RH; Socinski MA; Edelman MJ; Belani CP; Gonin R; Catalano RB; Marinucci DM; Comis RL; Obasaju CK; Chen R; Monberg MJ; Treat J;
    Crit Rev Oncol Hematol; 2011 May; 78(2):162-71. PubMed ID: 20413322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
    Greco FA; Spigel DR; Kuzur ME; Shipley D; Gray JR; Thompson DS; Burris HA; Yardley DA; Pati A; Webb CD; Gandhi JG; Hainsworth JD
    Clin Lung Cancer; 2007 Sep; 8(8):483-7. PubMed ID: 17922972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
    Sederholm C; Hillerdal G; Lamberg K; Kölbeck K; Dufmats M; Westberg R; Gawande SR
    J Clin Oncol; 2005 Nov; 23(33):8380-8. PubMed ID: 16293868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
    Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC
    Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.